Dr. Larsen Discusses Outcomes for AYA ALL Patients

Eric Larsen, MD
Published: Thursday, Jun 07, 2012

Eric Larsen, MD, medical director of the Maine Children's Cancer Program, discusses a large phase III study that compared outcomes between adolescent and young adult (AYA) and younger patients with high-risk acute lymphoblastic leukemia (HR-ALL).

The study included 501 AYA patients, who were defined as those being age 16 to 30, and 466 younger patients age 1 to 15. Larsen notes that the power of this study was its ability to enroll enough patients to produce a statistically significant outcome.

In general, the AYA patients demonstrated worse outcomes, more relapses, and lower rates of both event-free and overall survival. Additionally, Larsen notes these patients had a very high rate of remission deaths, which he defines as a death that is unrelated to the HR-ALL, during remission, while continuing the therapy.

Larsen believes these findings point to the need for new strategies that reduce relapses and toxicities for the AYA group of patients.

Eric Larsen, MD, medical director of the Maine Children's Cancer Program, discusses a large phase III study that compared outcomes between adolescent and young adult (AYA) and younger patients with high-risk acute lymphoblastic leukemia (HR-ALL).

The study included 501 AYA patients, who were defined as those being age 16 to 30, and 466 younger patients age 1 to 15. Larsen notes that the power of this study was its ability to enroll enough patients to produce a statistically significant outcome.

In general, the AYA patients demonstrated worse outcomes, more relapses, and lower rates of both event-free and overall survival. Additionally, Larsen notes these patients had a very high rate of remission deaths, which he defines as a death that is unrelated to the HR-ALL, during remission, while continuing the therapy.

Larsen believes these findings point to the need for new strategies that reduce relapses and toxicities for the AYA group of patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x